OssDsign AB intends to carry out a directed new share issue
Summary
OssDsign has engaged Skandinaviska Enskilda Banken AB (SEB) to investigate the conditions for the Directed New Share Issue through an accelerated bookbuilding procedure. The information was submitted for publication, through the agency of the contact persons set out above, on 29 November 2022, at 17:31 CET.OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the bodys own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Australia, Canada, Hong Kong, Japan, Singapore, South Africa or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements.